Corticosteroid News and Research

RSS

Corticosteroids are any steroid hormones made in the adrenal cortex (the outer part of the adrenal gland). They are also made in the laboratory. Corticosteroids have many different effects in the body, and are used to treat many different conditions. They may be used as hormone replacement, to suppress the immune system, and to treat some side effects of cancer and its treatment. Corticosteroids are also used to treat certain lymphomas and lymphoid leukemias.

Anti-metabolic syndrome efforts needed for young ALL survivors

Children with acute lymphoblastic leukemia are at risk for developing the metabolic syndrome during maintenance therapy, suggest study findings.

5 Mar 2013

Two asthma medications combined in one inhaler more effective than recommended treatment

Two large randomised trials published to coincide with the launch of The Lancet Respiratory Medicine provide compelling new evidence that using two types of common asthma medications combined in one inhaler for both preventive and rescue treatment (Single inhaler Maintenance and Reliever Therapy; SMART) is more effective at reducing attacks than guideline-based treatment in adults whose asthma is not well controlled, and is safe and well tolerated.

5 Mar 2013

Ampio Pharmaceuticals starts Optina clinical trial

Ampio Pharmaceuticals, Inc. announced oral dosing of the first patient in a 505(b)(2) clinical trial of the investigational drug Optina in diabetic macular edema.

27 Feb 2013

Intense acupuncture shows promise for Bell’s palsy rehabilitation

Intense or “de qi” acupuncture produces significantly better results when added to prednisone treatment than low-intensity acupuncture for patients with Bell’s palsy, show findings from a randomized controlled trial.

26 Feb 2013

Research into why young adults overuse short-acting bronchodilators

The high cost of medication, stigmatisation and poor acceptance of their condition are causing young adults to take a dangerous approach to managing their asthma, according to new research published today in the journal BMJ Open.

22 Feb 2013

Sleep disorder linked to reduced life quality in asthma patients

Quality of life is significantly decreased in adult patients with asthma who are at high risk for obstructive sleep apnea, results from a Korean study show.

15 Feb 2013

EMAS publishes clinical guide on lichen sclerosus in Maturitas journal

Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today the publication of a clinical guide by the European Menopause and Andropause Society (EMAS) in its journal Maturitas on lichen sclerosus with summary recommendations.

15 Feb 2013

Santarus launches UCERIS for induction of remission in patients with ulcerative colitis

Santarus, Inc. announced today the U.S. commercial launch of UCERIS (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis.

14 Feb 2013

Steroid therapy impedes Duchenne’s cardiomyopathy

Steroid therapy is associated with a considerable reduction in all-cause mortality and new-onset and progressive cardiomyopathy in patients with the debilitating X-linked disease Duchenne muscular dystrophy.

11 Feb 2013

Celgene's Pomalyst receives FDA approval for treatment of multiple myeloma

The U.S. Food and Drug Administration today approved Pomalyst (pomalidomide) to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs.

10 Feb 2013

Steroid injections not advisable for tennis elbow

Results from a placebo-controlled trial show that patients given corticosteroid injections for treatment of unilateral lateral epicondylalgia, or tennis elbow, have a worse outcome after 1 year than those treated with placebo.

6 Feb 2013

Cytos announces Novartis termination from NIC002 smoking cessation project

Cytos Biotechnology Ltd today announced that Novartis will discontinue the NIC002 project, which is a therapeutic vaccine candidate for the treatment of nicotine addiction.

23 Jan 2013

FDA approves Ampio’s IND for Optina for treatment of diabetic macular edema

Ampio Pharmaceuticals, Inc. announced today that the FDA has accepted the Company's IND for Optina™ for the treatment of diabetic macular edema (DME). Ampio plans to commence enrollment in a clinical trial in the first quarter of 2013. The FDA granted Optina™ 505(b)(2) status in July, 2012. Drugs designated under this pathway can be approved on a single trial.

22 Jan 2013

FDA approves Santarus’ UCERIS for induction of remission in patients with ulcerative colitis

Santarus, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved UCERIS (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis.

16 Jan 2013

Update on Cytos’ CYT003 Phase 2b trial for allergic asthma

Cytos Biotechnology Ltd today announced an update on the Phase 2b clinical trial with its lead product candidate, CYT003, in allergic asthma.

16 Jan 2013

Asthma linked to pulmonary embolism risk

Patients with asthma have an increased risk for pulmonary embolism, show Dutch findings.

8 Jan 2013

Merck’s resubmission of the NDA for suggammadex sodium injection accepted for review by the FDA

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the resubmission of the New Drug Application (NDA) for sugammadex sodium injection has been accepted for review by the U.S. Food and Drug Administration (FDA). Merck expects the FDA’s review to be completed in the first half of 2013.

7 Jan 2013

Soligenix's OrbeShield granted FDA oral BDP orphan drug designation

Soligenix, Inc., a development stage biopharmaceutical company, announced today that the Office of Orphan Products Development of the US Food and Drug Administration (FDA) has granted orphan drug designation to OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP) for the prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster.

2 Jan 2013

Extended steroid treatment fails to reduce pediatric nephrotic relapse

Study findings indicate that extending initial prednisolone treatment durations in patients with pediatric nephrotic syndrome from 3 to 6 months without increasing the overall dose does not reduce the number of relapses.

22 Dec 2012

New once-daily dual bronchodilator effective in COPD

A once-daily, inhaled, fixed-dose dual bronchodilator combination has greater efficacy than twice-daily salmeterol plus fluticasone for the treatment of chronic obstructive pulmonary disease, results of the phase III ILLUMINATE trial show.

18 Dec 2012